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Introduction
‘‘Science knows no country, because knowledge
belongs to humanity, and is the torch which
illuminates the world.’’—Louis Pasteur
Leishmaniasis remains one of the world’s
most devastating neglected tropical diseas-
es, causing substantial mortality and con-
tributing to nearly 2 million disability-
adjusted life years. The true global burden
of leishmaniasis, however, is unknown. The
Middle East and North Africa (MENA)
region is endemic for many forms of
leishmanisis and has hosted many recent
epidemic outbreaks. A research and policy
conference, LEISHMANIA: Collaborative
Research Opportunities in North Africa
and the Middle East, was held in June 2009
in Tunisia to promote international collab-
oration between the United States (US) and
the countries most affected by Old World
leishmaniasis (see Table 1 for a list of par-
ticipating countries). Supported by the US
National Institute of Allergy and Infectious
Diseases, National Institutes of Health
(NIH), and hosted locally by the Institute
Pasteur de Tunis, approximately 100
scientists and administrators from the US
and MENA countries met to share critical
information and to identify the major
obstacles for translating scientific break-
throughs into innovative strategies for
reducing the burden of leishmaniasis. The
participants identified three crucial areas as
requiring reinforcement and growth: trans-
lation of laboratory discoveries into field-
applications, increased research capacity in
endemic countries, and the creation of a
leishmaniasis reagent repository (Figure 1).
Our hope is that these recommendations
will be adopted by research, funding, and
policy institutions alike to have a greater
impact at controlling leishmaniasis through-
out the world.
Leishmaniasis in the Middle
East and North Africa
L e i s h m a n i a s i si sac o m p l e x ,m u l t i - s p e c -
trum, sand fly–transmitted disease (Figure 2),
with symptoms ranging from self-limiting
cutaneous lesions to fatal visceral disease.
While the species of Leishmania initiating
the infection primarily dictates clinical
presentation, a single Leishmania species
can elicit a range of pathologies [1,2,3].
The specific factors that influence clinical
outcome of these infections remains to be
completely elucidated, but likely is influ-
enced by host genetics or immune re-
sponses [4], potentially different sand fly
vector species or populations [5,6,7], and/
or the presence of Leishmania spp. hybrids
[8,9].
Although the World Health Organiza-
tion (WHO) has designated leishmaniasis
as one of the 15 most neglected tropi-
cal diseases, the global morbidity due
to leishmaniasis remains underestimated
due to misdiagnosis and inadequate re-
porting guidelines. In the MENA region
alone, nearly 100,000 cases of leishman-
iasis in 2008 were reported to the WHO;
however, some nations only report for one
of the various clinical pathologies, and
other countries fail to report all together
[10]. Epidemics of leishmaniasis often
are associated with war, human migra-
tion, and anthroponotic environmental
change associated with agricultural prac-
tices or urbanization. The key factors
driving the risk, severity, and temporal-
spatial trends of disease, however, are
presently unknown, and predictive tools
for epidemic peaks and geographic
spread of leishmanial disease are lacking
[11].
Translation of Laboratory
Discoveries into Field
Applications
‘‘Science and the applications of science
bound together as the fruit of the tree which
bears it.’’ —Louis Pasteur
Science is in the midst of a technological
explosion, and the next wave of scientific
progress will involve translating these
advancements into practical implementa-
tion policies in disease-endemic regions.
Many novel techniques are furthering our
understanding of various aspects of Leish-
mania transmission, disease, and sand
fly biology, tools that hold promise for
bridging the bench to the bedside. Unfor-
tunately, this revolution has not translated
into meaningful control measures. Ad-
vancement in three major priority areas,
molecular diagnostics, clinical research,
and knowledge sharing and standardiza-
tion, is necessary to push the leishmaniasis
field towards translational results (Table 2).
Molecular Diagnostics
Specific parasite identification methods
are essential if the complexities of leish-
manial disease manifestation are to be
elucidated; to effectively impact epidemi-
ological studies as well as clinical treat-
ment, these diagnostic tools must be re-
liable, inexpensive, easy to use, and pro-
vide quick results. Comparative genome
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will greatly enhance development of novel
molecular approaches to identify different
Leishmania species and strains, and as next
generation sequencing methods become
more affordable, genome sequence infor-
mation will be more easily obtainable for
clinical isolates. Bolstering genomics re-
search in general and increasing genomics
capacity in regional environments is cru-
cial if we hope to unravel the complex
dynamics of leishmaniasis.
Molecular tool development also is
essential to produce a complete epidemi-
ological picture of vector distributions and
how these species correlate with the cur-
rent state of leishmaniasis in the MENA
region. New insights concerning sand fly
biology will likely be provided with the
completion of the ongoing genome pro-
jects of two sand fly species, Phlebotomus
papatasi and Lutzomyia longipalpis.
Clinical Research
Development of a vaccine to prevent
leishmaniasis has been motivated by the
observation that a cured infection pro-
tects against re-infection. While laboratory
studies and anecdotal evidence indicate
that ‘‘natural infection’’ protects from
severe disease, true validation in the field
is necessary, as cases of re-infection have
been reported [12,13]. Model systems
certainly can provide critical information,
but they never truly mimic the disease
dynamics in nature. Although delineating
the mechanisms that lead to parasite
establishment and tissue-specific immunity
in humans remains an ethical challenge,
clinical research in leishmaniasis-endemic
regions needs to be expanded. In addition
to the evaluation of vaccine trials and
anti-leishmanial drugs, implementation of
large, longitudinal, cohort studies will
improve the understanding of that natural
history of Leishmania infection and its
transmission dynamics, as well as the para-
meters that lead to the wide disease
spectrum.
Regulatory bottlenecks due to inade-
quate administrative frameworks often
hinder clinical research activity in dis-
ease-endemic countries. The international
research community could bridge this in-
frastructure gap by facilitating clear and
coordinated international human subjects’
research protection (HRP) policy confor-
mity through streamlined procedures for
establishing and registering Institutional
Review Boards and Federalwide Assur-
ance compliance in all nations. Further-
more, research institutions and private
industry should be encouraged to establish
policies for the ease of executing material
transfer agreements (MTA) and non-
disclosure arrangements (NDA) in low-
and middle-income countries.
Knowledge Sharing and
Standardization
Rapid advances are being made in the
leishmaniasis field, some of which are
opening new avenues for investigation
and hold promise for translational applica-
tion. For these breakthroughs to be effec-
tive, however, technology needs to be effi-
ciently transferred to regional scientists.
Not only is knowledge sharing essential
between scientists of resource-rich and low-
and middle-income nations, there also is
a dire necessity for assay standardization
between the entire leishmaniasis research
community. Clearguidelines and best prac-
tices should be created for assessing vaccine
efficacy and validating chemotherapies.
Also essential is the generation of guide-
lines for the development and implemen-
tation of field-based studies and clinical
trials. Standardization of experimental de-
sign, reporting statistics, and clinical pro-
tocols will be required across nations to
adequately derive conclusions from multi-
ple investigations. Furthermore, development
of protocols to assess pertinence, effective-
ness, and robustness of surveillance pro-
grams are desperately needed.
Successful implementation of these clinical
studies will only advance the leishmaniasis
Figure 1. Policy recommendations for the translation of laboratory discoveries into
field applications for the control of leishmanisis.
doi:10.1371/journal.pntd.0001219.g001
Table 1. Countries Represented.
Country Scientists
Afghanistan 1
Algeria 1
Egypt 4
Iran 3
Jordan 1
Lybia 1
Mali 1
Morocco 2
Palestinian Authority 2
Sudan 8
Syria 1
Tunisia 30
Turkey 1
United States of America 26
doi:10.1371/journal.pntd.0001219.t001
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researchers, policy makers, and practitioners.
Timely information dissemination will be
required as the leishmaniasis field continues
to expand; such exchange could appear in
public digital libraries, through development
of secure Web sites for clinical data, or by
implementation of smaller regional meetings
that foster interaction between scientists,
clinicians, and government personnel.
Capacity Building
Increased investments in research,
availability of laboratory facilities, and
close collaboration among scientists
would greatly advance the leishmaniasis
field. Strengthening the connections be-
tween education, research, and society
are essential factors and require certain
building blocks to assure its proper
structure. However, in resource-poor
l o c a t i o n si ti sd i f f i c u l tt oe s t a b l i s ha n d
sustain such cooperative enterprises.
This arduous task requires global capac-
ity building in science and technology,
and active participation of the interna-
tional scientific community could have
tremendous effects.
The persistent loss of national scientific
talent is an important issue that low- and
middle-income countries are facing and is
a major obstacle to the proper establish-
ment of research activities in endemic
countries. In order to be successful, scien-
tific institutions need access to infrastruc-
ture, technical support, and trained scien-
tists. By creating a thriving scientific
atmosphere, researchers will be retained
and motivated. In order to increase
scientific capacity in the MENA region,
focused efforts in the following areas are
necessary:
Figure 2. MENA leishmaniasis. Although at least 20 Leishmania spp. infect humans worldwide, the primary epidemiologically relevant species in
the MENA region are L. major, L. tropica, L. infantum, and L. donovani, transmitted by approximately 25 different Phlebotomus spp. Etiological agents
of visceral leishmaniasis (VL) in MENA include L. donovani, L. infantum, and occasionally L. tropica. Cutaneous leishmaniasis (CL) caused by L. major, L.
tropica, and L. infantum differ slightly in lesion presentation depending on the species. As with vector species, a variety of animal hosts have been
implicated as reservoirs in the transmission of zoonotic leishmaniasis, including rodents, hyraxes, and canids. For CL caused by L. major, the primary
cycle is zoonotic between P. papatasi (shown) and Psammoys (shown) and Meriones rodents. Although hyraxes have been implicated as a reservoir
host for L. tropica, transmission is thought to be primarily anthroponotic as is the VL agent, L. donovani. Mediterranean VL caused by L. infantum is
typically zoonotic where candids are the primary reservoir and man is an accidental host; however, anthroponitic cycles also have been characterized.
Regardless of species or clinical manifestation, all Leishmania species infecting humans are transmitted by the bite of an infected sand fly. During a
blood meal, metacyclic promastigotes are released by the sand fly and enter the skin of the vertebrate host. Leishmania parasites infect cells of the
myeloid lineage, including neutrophils, followed by macrophages and dendritic cells (shown). These parasites reside within a phagolysosome where
they differentiate into a dividing, aflagellated amasitogotes. Sand flies take up parasites when feeding on an infected host. Infected host cells are
lysed and amastigotes differentiate into flagellated procyclic promastigotes that attach to the midgut of the sand fly vector. Subsequent
development and migration towards the anterior end of the sand fly completes the cycle. Photo Credits: P. papatasi courtesy of Tim Gathany, Center
for Disease Control Photo Services; Psammomys obesus from http://commons.wikimedia.org/wiki/File:Psammomys_obesus_01.jpg; rock hyrax from
http://www.marietta.edu/,biol/biomes/biome_main.htm.
doi:10.1371/journal.pntd.0001219.g002
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entists and institutions, including both
academic and public health organiza-
tions, must be fostered and supported
by funding agencies, governments, and
private and public institutions. Proac-
tive actions should to be taken to
develop mutually advantageous col-
laborative projects through directed
seed funding.
2. Development of institutional partner-
ships with lasting student and faculty
exchange programs. Sandwich training
of PhD students is particularly useful at
bringing and retaining regional scientists.
3. The organization of training workshops
andcoursescanserveasamechanismof
active collaboration among different
institutes. These training modules
should be located in leishmaniasis-
endemic countries for greater accessi-
bility to scientists from these areas.
4. Creation of Web sites where subject-
specific teaching materials and assay
protocols are easily accessed.
5. Availability of visiting lectureships and
travel grants for participation in inter-
national scientific meetings to scientists,
post-graduate students, and technicians
from disease-endemic countries should
be increased.
6. Establishment and support of local and
international scientific associations that
meet on a regular basis would increase
information sharing among endemic
scientists and policy makers.
Creation of a Leishmania/Sand
Fly Reagent Repository
Another priority area that will increase
the research capacity in leishmaniasis-
endemic countries is the creation of a
centralized leishmaniasis reagent reposito-
ry. An enterprise such as the Malaria Re-
search and Reference Reagent Resource
Center (MR4) housed at the American
Type Culture Collection (ATCC) would
greatly enhance the availability of leish-
manisis reagents to resource-poor nations.
Genomic databases, like TriTypDB (http://
tritrypdb.org/) for kinetoplastid organ-
isms, EuPathDB (http://eupathdb.org/)
for eukaryotic pathogens, and Vector-
Base (http://www.vectorbase.org/) for ar-
thropod vectors of disease, that manage
genmic data and support centralized
bioinformatics tools have already provided
essential resources to researchers from
disease-endemic countries. The next criti-
cal step, however, is for the genomic
reagents connected to genome projects to
be readily accessible to the international
research community. In addition to geno-
mic tools, a depot stocking Leishmania
strains and mutants, clinical isolates, tissue
samples, and other leishmaniasis research
reagents would improve the access of such
materials to scientists worldwide. One
obstacle to effectively controlling leishman-
iasis is an inadequate picture of the sand fly
strains that can transmit Leishmania para-
sites. As molecular systematics is a rapidly
evolving field, type specimens for future
analysis also could be stored and distribut-
ed by a leishmaniasis reagent center.
In addition to increased access of re-
agents to international scientists, an added
benefit of a leishmaniasis repository would
be the availability of Leishmania strains and
other reagents for verification by multiple
laboratories and additional experimental
platforms. Moreover, easy access of mate-
rials might encourage scientists from other
disciplines to apply their expertise to the
leishmaniasis field, bringing fresh ideas
and approaches to controlling these de-
structive diseases.
There are currently limited Leishmania
repositories in the United Kingdom,
France, and Brazil, as well as sand fly
collections housed by universities and
museums in different nations. However,
no centralized location exists that curates,
stores, and distributes these resources to
the entire international research commu-
nity. As leishmaniasis research continues
to expand, the financial cost to these
smaller storage facilities may become too
much of a burden. International collabo-
rative leishmaniasis research would be
greatly strengthened if a sustained leish-
maniasis repository was created and ease
the cost and difficulty of the distribution of
scientific samples across international bor-
ders. Clearly, such an enterprise would
require oversight and funding, and strict
guidelines for sample submission and
quality control must be implemented. Like
MR4, which is supported by NIH and
serves the malaria community, such a
Table 2. Leishmaniasis: Road to Translation.
Translation of Laboratory Discoveries to Field Application
Molecular Diagnostics Clinical Research Information Sharing
Leishmania Species Administrative Infrastructure Assay Standardization
Sand Fly Species Best Practices Guidelines Digital Libraries
Genomics Research Streamlined HRP/MTA/NDA Data Sharing
Capacity Building
Partnerships Training Infrastructure
Institutional PhD Sandwich Programs Laboratory Facilities
Scientific Collaborations Regional Workshops Administrative
Seed Funding/Travel Grants Web-based Courses Regional Meetings
Repository
Leishmania Sand Flies Reagents
Clinical Isolates Type Specimens Hybridomas
Parasite Strains Tissues Genomic Resources
Molecular Tools
doi:10.1371/journal.pntd.0001219.t002
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public and private agencies and would be
best developed through a competitive bid
process.
Summary
The US-MENA Leishmaniasis confer-
ence provided an unprecedented opportu-
nity for scientists to interact and focus on
leishmaniasis research issues specific to the
MENA region and resulted in several
successful grant proposals funded through
the Civilian Research and Development
Foundation. The collaborations that arose
from this conference will certainly influ-
ence leishmaniasis control in the MENA
region specifically; moreover, the discus-
sions and recommendations also have
implications for the leishmaniasis field as
a whole.
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